PYPD — PolyPid Ltd.

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: IL
• Exchange: NASDAQ
• Employees: 57
• Website: https://www.polypid.com

Latest SEC filings for PYPD

• 6-K — 2026-10-01
• 6-K — 2026-10-01
• 6-K — 2026-08-12
• S-8 — 2026-08-12
• 6-K — 2026-08-12
• 6-K — 2026-07-29
• 6-K — 2026-07-21
• 6-K — 2026-07-15
• 6-K — 2026-06-10
• 6-K — 2026-06-01

Latest PYPD news

• 2026-10-21 — PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026 (GlobeNewswire Inc.)
• 2026-10-04 — PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data (marketbeat.com)
• 2026-10-01 — European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX₁₀₀ (globenewswire.com)
• 2026-10-01 — PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities (globenewswire.com)

Abrir análisis completo

Educational tool only — not investment advice.